Sarepta rises on three-year Elevidys data
Source: SeekingAlpha
2026-01-26 08:55:36 ET
More on Sarepta Therapeutics
- Sarepta Preliminary Results: Not What The Market Wanted To Hear
- Sarepta Therapeutics: Is Elevidys A Bust?
- Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Sarepta jumps on upcoming release of 3-year Elevidys data
- Sarepta guides Q4 sales below estimates
Read the full article on Seeking Alpha
For further details see:
Sarepta rises on three-year Elevidys data
Sarepta Therapeutics Inc.
NASDAQ: SRPT
SRPT Trading
-4.47% G/L:
$17.085 Last:
701,594 Volume:
$17.54 Open:
SRPT Latest News
February 27, 2026 09:00:00 am
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
SRPT Stock Data
$1,921,797,010
96,823,361
N/A
132
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
